New York, Feb 9, 2026, 11:50 EST — Regular session
- Boston Scientific dropped roughly 2.6% in early trading, adding to the declines seen after last week’s earnings release.
- Electrophysiology and Watchman demand remain top of mind for investors following the most recent quarterly results.
- The next major test for the heart-rhythm business arrives with the Heart Rhythm 2026 meeting slated for late April.
Boston Scientific was off 2.6% at $74.29 as of 11:50 a.m. EST Monday, slipping from an earlier session low of $74.12. Shares dropped even as the SPDR S&P 500 ETF Trust (SPY) advanced roughly 0.6%.
The latest action leaves the medical-device maker still feeling the heat, following last week’s abrupt reset. Investors have cooled on the high-growth narrative, which offered little margin for error. Some of the recent selling seems mechanical, yet it hasn’t let up.
Electrophysiology is getting the spotlight here — these are devices for minimally invasive heart rhythm procedures, a business many investors see as key to Boston Scientific’s growth story. Then there’s Watchman, the implant aimed at lowering stroke risk for atrial fibrillation patients; that’s also been under scrutiny.
Fourth-quarter electrophysiology sales landed at $890 million—missing the Street’s $933 million target, Reuters said. Citi’s Joanne Wuensch called investors’ “worries…not misplaced.” JPMorgan flagged legitimate doubts over the trajectory for both businesses. Still, CEO Michael Mahoney told analysts he was “really pleased” with the segment’s 35% organic growth, adding the market could expand by about 15% in 2026. reuters.com
Boston Scientific turned in fourth-quarter net sales of $5.286 billion, with adjusted earnings landing at $0.80 a share. Looking ahead, the company projects organic net sales growth between 10% and 11% through 2026, and expects adjusted EPS to range from $3.43 to $3.49. For the first quarter, Boston Scientific is aiming for organic growth in the 8.5% to 10% band, with adjusted earnings per share seen at $0.78 to $0.80. The company defines “organic” as excluding currency shifts, plus certain acquisition and divestiture impacts.
Medical-device stocks showed a mixed picture. Abbott barely budged. Medtronic and Stryker each dropped roughly 1%.
Following the results, a handful of banks lowered their price targets but stuck with buy-oriented ratings, MT Newswires reports via MarketScreener. Citigroup dropped its target to $102 from $130. JPMorgan took theirs down to $100 from $135. Wells Fargo moved to $94 from $125, according to the notes.
There’s a chance the electrophysiology miss signals not just a timing issue, but mounting competition—something that can hit procedure-centric businesses fast. If U.S. demand for Watchman slips further, investors may stay wary when it comes to the company’s growth outlook.
Boston Scientific shows up in plenty of large-cap healthcare funds, so the selloff has rippled beyond just this stock. The question now: will management convince investors the main growth engines are still running, and avoid another downward revision?
Looking ahead, the next big electrophysiology event lands April 23-26 in Chicago: Heart Rhythm 2026. It’s the go-to spot for fresh clinical data and product announcements from major players. Boston Scientific’s heart-rhythm prospects—investors will be watching for any signs of steadiness in that momentum.
